Schedule 13D ownership disclosure

Design Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 25056L103

Event date: 2026-03-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • SR One Capital Fund I Aggregator, LPReported CIK 0001848319

    Shares: 6,526,476.00 · Class: 10.6%

  • SR One Capital Partners I, LP

    Shares: 6,526,476.00 · Class: 10.6%

  • SR One Capital Management, LLC

    Shares: 6,526,476.00 · Class: 10.6%

  • Simeon George

    Shares: 6,607,892.00 · Class: 10.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001072613-26-000257
Form type
SCHEDULE 13D/A
Filer
Design Therapeutics, Inc.
CIK
CIK 1807120
Filed
Mar 11, 2026
Reporting period
Mar 09, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub